Cases & Deals

Rain Therapeutics expands patent portfolio related to clinical stage cancer therapies

Client(s) Rain Therapeutics Inc.

Jones Day advised Rain Therapeutics Inc. in connection with global patent portfolio development related to a hypoxia-activated prodrug of a potent pan-HER inhibitor, Tarloxotinib (Tarlox), for the treatment of non-small cell lung cancer in patients with EGFR and HER exon 20 insertion mutations.